Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes

By Gredal C.   Rosenfalck A. M.   Dejgaard A.   Hilsted J.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 67, Iss. 3, 2007-01 ,pp. : 327-336

Informa Healthcare

Access to resources Recommend Favorite

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 636-644

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study

By Shestakova M.   Sharma S. K.   Almustafa M.   Min K. W.   Ayad N.   Azar S. T.   Danciulescu R.   Khutsoane D.   Guler S.  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3209-3214

Informa Healthcare

Access to resources Recommend Favorite

Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice

By Vähätalo Markku   Rönnemaa Tapani   Viikari Jorma  

Scandinavian Journal of Primary Health Care, Vol. 25, Iss. 3, 2007-01 ,pp. : 147-153

Informa Healthcare

Access to resources Recommend Favorite

Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 659-664

John Wiley & Sons Inc

Access to resources Recommend Favorite